Venture Life Group PLC
(“Venture Life” or the “Company”)
Venture Life (AIM: VLG), the international consumer self-care group focused on developing, manufacturing and commercialising products for the self-care market announces that, on 16 April 2018, Gianluca Braguti, a Director of the Company, transferred a total of 2.3 million ordinary shares of 0.3p each in the Company for nil consideration, subject to the terms of a lock-in deed as described below, to his two sons and his former wife (the 'Locked-in Parties'). Following the transaction, Gianluca Braguti's beneficial interest is 4,785,459 ordinary shares representing 13.0 per cent. of the Company's issued share capital.
The Locked-in Parties have agreed not to dispose of their holdings in the Company (the 'Locked-in Shares') for a period of 24 months commencing on the date when the relevant ordinary shares are registered in the name of a Locked-in Party (the 'Lock-in Period'). In addition, the Locked-in Parties have agreed to an orderly market arrangement whereby, following expiry of the Lock-in Period for as long as Gianluca Braguti is a Director of the Company, they will only dispose of their Locked-in Shares via the Company's broker. The Locked-In Parties have also agreed that, for as long as Gianluca Braguti is a Director of the Company, all voting rights attached to their Locked-in Shares will be exercised as directed by him.
Venture Life Group PLC +44 (0) 1344 742870
Jerry Randall, Chief Executive Officer
James Hunter, Chief Financial Officer
Panmure Gordon (UK) Limited (Nominated Adviser and Joint Broker) +44 (0) 20 7886 2500
Freddy Crossley/Peter Steel/Duncan Monteith (Corporate Finance)
Tom Salvesen (Corporate Broking)
Turner Pope Investments (TPI) Ltd (Joint Broker) +44 (0) 20 3621 4120
James Pope/Ben Turner
Walbrook PR firstname.lastname@example.org or +44 (0) 20 7933 8780
Paul McManus/Anna Dunphy +44 (0) 7980 541 893 / +44 (0) 7876 741 001
About Venture Life (www.venture-life.com)
Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the ageing population. The Group’s product portfolio includes some key products such as the UltraDEX oral care products range, food supplements for lowering cholesterol and maintaining brain function, medical devices for women’s intimate healthcare and haemorrhoids and dermo-cosmetics for addressing the signs of ageing.
The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group’s international distribution partners.
Through its Development & Manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.